Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10571875
Filing Date		2006-04-05
First Named Inventor COE		LIEDENBAUM
Art Unit		
Examiner Name		
Attorney Docket Number		NL031214

				U.S.	PATENTS		Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevan s Appear
	1	4775967		1988-10-04	SHIMODA ET AL		
	2	4949329		1990-08-14	FURMAN ET AL		
	3	5657164		1997-08-12	SHURMAN		
	4	5835466		1998-11-10	SHIMODA		
	5	6198706	B1	2001-03-06	ZUCKER		
If you wis	n to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document		
	1						
If you wis	n to a	dd additional U.S. Publis	hed Ap	plication citation	n information please click the Ad	d button.	Add
					TENT DOCUMENTS		Remove

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Foreign Document

Country

Code2 i

Examiner Cite

Initial\* No Number3

Application Number		10571875
Filing Date		2006-04-05
First Named Inventor COEN		LIEDENBAUM
Art Unit		
Examiner Name		
Attorney Docket Number		NL031214

Name of Patentee or

Date Considered

Applicant of cited

Document

Pages.Columns.Lines

where Relevant
Passages or Relevant

Figures Appear

	1	03241530	JP		1991-10-28	TOSHIBA CORP		
	2	2002025066	JP		2002-01-25	SONY CORP		
	3	200249024	wo	A1	2002-06-20	KPENV		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţ5	
	1 ISR: PCT/IB2004052015 [							
	2	WRITTEN OPINION: PO	CT/IB2004/052015	i				
If you wie	h to a	dd additional non-naton	t literature docu	mont ci	tation informat	ion please click the Add	hutton Add	

Kind Publication

Codes Date

See, Kinz Ooder of USPTO Potent Decuments at yeary USETIO\_COLV or MEDF 981.04. \*\*Extent office that issued the document, by the two-lefter code (NEOC Standard ST.).\*\*To Appearse point of excurrent, the included or the year of the represent any process to seited in restored the year of the register compression to seited involved of the year of the register compression to the year of the register compression. \*\*Applicated is to place a check mark here if English targingsing the resistance is a set of the possible. \*\*Applicant is to place a check mark here if

EXAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10571875
Filing Date		2006-04-05
First Named Inventor COE		LIEDENBAUM
Art Unit		
Examiner Name		
Attorney Docket Number		NI 031214

#### CERTIFICATION STATEMENT

Please see	37	CFR 4	97	and	1 02	to	make the	annror	rista	بمامه	rtion	(e)	ı

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/MICHAEL E. BELK/	Date (YYYY-MM-DD)	2007-09-10
Name/Print	MICHAEL E. BELK	Registration Number	33357

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DING SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.